media – Page 629 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Scientists discover potential treatment to stop glaucoma in its tracks

Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, the world's second-leading cause of blindness.
- Source: Medicalxpress
- 497
- November 7, 2017
glaucoma lipid mediators neurodegenerative disease
Teva looks to sell generics in China through joint venture with Guangzhou Pharma

As the world’s largest generics maker, Teva still doesn’t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that by reportedly forming a joint venture with local company Guangzhou Pharma
- Source: Fiercepharma
- 536
- November 7, 2017
China generics Teva
New tissue-engineered blood vessel replacements one step closer to human trials

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doesn't contain any living cells at implantation. The vessel, that could be used as an "off the shelf" graft for kidney dialysis patients, performed well in a recent study with nonhuman primates.
- Source: worldpharmanews
- 547
- November 7, 2017
biological blood vessel kidney dialysis Researches
‘Precision Medicine’ may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the world's more diverse populations, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and the Keck School of Medicine of the University of Southern California (USC).
- Source: worldpharmanews
- 559
- November 6, 2017
cancer oncology precision medicine Researches
Merck subsidiary StayWell acquires app maker MedHelp for undisclosed sum

To expedite its push into mobile health, Yardley, Pennsylvania-based StayWell announced today that it has acquired the mobile health portion of Silicon Valley-based MedHelp, which includes several consumer-facing mobile health apps.
- Source: mobihealthnews
- 503
- November 6, 2017
Company Insight health apps MedHelp Merck
FDA Widens Scope of Navigator – Information Tool for Expanded Access

FDA is committed to expanding access to safe and effective treatment options for patients with rare, debilitating, and sometimes fatal diseases. These patients face unique medical challenges. Sometimes there isn’t an FDA-approved drug to adequately address the needs of a patient with a rare disease. Therefore, the agency needs to take new steps to enable more patients with unmet needs to get access to promising treatments prior to full FDA approval.
- Source: blogs.fda.gov
- 584
- November 6, 2017
FDA orphan Policy treatment
Amgen, Novartis Rev Up for New Alzheimer’s Study

Amgen and Basel, Switzerland-based Novartis announced they have expanded their collaboration with the Banner Alzheimer’s Institute (BAI) to launch a new clinical trial in Alzheimer’s.
- Source: Pharmalive
- 693
- November 6, 2017
Alzheimer's API Clinical Trial Market Views
Shockwave Medical Announces $35 Million in New Financing

Shockwave Medical reported $35 million in new financing, an extension of the company’s previously announced $45 million Series C financing. New investor Fidelity Management & Research Company participated, along with certain funds and accounts advised by T. Rowe Price Associates, Inc., a returning investor.
- Source: Dicardiology
- 631
- November 6, 2017
Peripheral and Coronary Lithoplasty Systems Shockwave Medical
The fight against obesity–To tax or not to tax?

The debate explores whether food taxation is an indispensable strategy to correct obesity trends, or whether there should be other ways of approaching the problem.
- Source: Medicalxpress
- 510
- November 6, 2017
food taxation obesity
China’s Import and Export Report of Antineoplastic Drugs

Antineoplastic or anticancer drugs, affect the process of cell division i.e. are antiproliferative. They damage the DNA and initiate apoptosis, preventing the development and spread of neoplastic cells. Commonly used antineoplastic drugs can be divided into the following six categories: alkylating agents, anti-metabolites, anticancerous, antibiaties, aminoglutethimide and others. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, shares China’s Import and Export Report of Antineoplastic Drugs with you. General situation of global market of antineoplastic drugs According to the IMS’s latest report, “Global Oncology Trends 2017” showed that in 2016 the global market sales of antineoplastic drugs were 89.6 billion USD and 85 billion USD in 2015. Over the past five years, the global market of antineoplastic drugs has grown at a compound annual growth rate (CAGR) of 8.7% and is expected to exceed 147 billion USD by 2021. As indicated on the chart, the United States, the European Union and Japan are still the driving ...
- Source: Ddu
- 1,532
- November 3, 2017
anticancer Antineoplastic Market Reports neoplastic cells

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.